News from the Cold Chamber: Clinical Experiences of POLARx versus Arctic Front Advance for Single-Shot Pulmonary Vein Isolation

Cryoballoon (CB)-guided pulmonary vein isolation (PVI) represents a cornerstone in the treatment of atrial fibrillation (AF). Recently, a novel balloon-guided single shot device (POLARx, Boston Scientific) was designed. Our study aimed to compare the efficacy, safety and characteristics of the novel...

Full description

Bibliographic Details
Published in:Journal of Cardiovascular Development and Disease
Main Authors: Denise Guckel, Philipp Lucas, Khuraman Isgandarova, Mustapha El Hamriti, Leonard Bergau, Thomas Fink, Vanessa Sciacca, Guram Imnadze, Martin Braun, Moneeb Khalaph, Georg Nölker, Philipp Sommer, Christian Sohns
Format: Article in Journal/Newspaper
Language:English
Published: MDPI AG 2022
Subjects:
Online Access:https://doi.org/10.3390/jcdd9010016
https://doaj.org/article/cc4163b335c3488e8c3e1922f6464051
id ftdoajarticles:oai:doaj.org/article:cc4163b335c3488e8c3e1922f6464051
record_format openpolar
spelling ftdoajarticles:oai:doaj.org/article:cc4163b335c3488e8c3e1922f6464051 2023-05-15T14:59:18+02:00 News from the Cold Chamber: Clinical Experiences of POLARx versus Arctic Front Advance for Single-Shot Pulmonary Vein Isolation Denise Guckel Philipp Lucas Khuraman Isgandarova Mustapha El Hamriti Leonard Bergau Thomas Fink Vanessa Sciacca Guram Imnadze Martin Braun Moneeb Khalaph Georg Nölker Philipp Sommer Christian Sohns 2022-01-01T00:00:00Z https://doi.org/10.3390/jcdd9010016 https://doaj.org/article/cc4163b335c3488e8c3e1922f6464051 EN eng MDPI AG https://www.mdpi.com/2308-3425/9/1/16 https://doaj.org/toc/2308-3425 doi:10.3390/jcdd9010016 2308-3425 https://doaj.org/article/cc4163b335c3488e8c3e1922f6464051 Journal of Cardiovascular Development and Disease, Vol 9, Iss 16, p 16 (2022) atrial fibrillation catheter ablation cryoballoon single-shot ablation devices Diseases of the circulatory (Cardiovascular) system RC666-701 article 2022 ftdoajarticles https://doi.org/10.3390/jcdd9010016 2022-12-31T14:47:37Z Cryoballoon (CB)-guided pulmonary vein isolation (PVI) represents a cornerstone in the treatment of atrial fibrillation (AF). Recently, a novel balloon-guided single shot device (POLARx, Boston Scientific) was designed. Our study aimed to compare the efficacy, safety and characteristics of the novel CB system with the established one (Arctic Front Advance (Pro), AFA, Medtronic). A total number of 596 patients undergoing CB-guided ablation for AF were included. 65 patients (65.0 ± 11.6, 31% female) undergoing PVI with the POLARx were compared to a cohort of 531 consecutive patients (63.0 ± 27.9, 25% female) treated with AFA. Acute PVI was achieved in all patients (n = 596, 100%). Total procedure duration (POLARx 113.3 ± 23.2 min, AFA 100.9 ± 21.3 min; p < 0.001) and fluoroscopy time (POLARx 10.5 ± 5.9 min, AFA 4.8 ± 3.6 min; p < 0.001) were significantly longer in the POLARx group. The POLARx balloon achieved significantly lower nadir temperatures (POLARx −57.7 ± 0.9 °C, AFA −45.1 ± 2.6 °C; p < 0.001) and a significantly higher percentage of pulmonary veins successfully isolated with the first freeze ( p = 0.027 *). One major complication occurred in the POLARx (2%) and three (1%) in the AFA group. Both ablation systems are comparably safe and effective. AF ablation utilizing the POLARx system is associated with longer procedure and fluoroscopy times as well as lower nadir temperatures. Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic Journal of Cardiovascular Development and Disease 9 1 16
institution Open Polar
collection Directory of Open Access Journals: DOAJ Articles
op_collection_id ftdoajarticles
language English
topic atrial fibrillation
catheter ablation
cryoballoon
single-shot ablation devices
Diseases of the circulatory (Cardiovascular) system
RC666-701
spellingShingle atrial fibrillation
catheter ablation
cryoballoon
single-shot ablation devices
Diseases of the circulatory (Cardiovascular) system
RC666-701
Denise Guckel
Philipp Lucas
Khuraman Isgandarova
Mustapha El Hamriti
Leonard Bergau
Thomas Fink
Vanessa Sciacca
Guram Imnadze
Martin Braun
Moneeb Khalaph
Georg Nölker
Philipp Sommer
Christian Sohns
News from the Cold Chamber: Clinical Experiences of POLARx versus Arctic Front Advance for Single-Shot Pulmonary Vein Isolation
topic_facet atrial fibrillation
catheter ablation
cryoballoon
single-shot ablation devices
Diseases of the circulatory (Cardiovascular) system
RC666-701
description Cryoballoon (CB)-guided pulmonary vein isolation (PVI) represents a cornerstone in the treatment of atrial fibrillation (AF). Recently, a novel balloon-guided single shot device (POLARx, Boston Scientific) was designed. Our study aimed to compare the efficacy, safety and characteristics of the novel CB system with the established one (Arctic Front Advance (Pro), AFA, Medtronic). A total number of 596 patients undergoing CB-guided ablation for AF were included. 65 patients (65.0 ± 11.6, 31% female) undergoing PVI with the POLARx were compared to a cohort of 531 consecutive patients (63.0 ± 27.9, 25% female) treated with AFA. Acute PVI was achieved in all patients (n = 596, 100%). Total procedure duration (POLARx 113.3 ± 23.2 min, AFA 100.9 ± 21.3 min; p < 0.001) and fluoroscopy time (POLARx 10.5 ± 5.9 min, AFA 4.8 ± 3.6 min; p < 0.001) were significantly longer in the POLARx group. The POLARx balloon achieved significantly lower nadir temperatures (POLARx −57.7 ± 0.9 °C, AFA −45.1 ± 2.6 °C; p < 0.001) and a significantly higher percentage of pulmonary veins successfully isolated with the first freeze ( p = 0.027 *). One major complication occurred in the POLARx (2%) and three (1%) in the AFA group. Both ablation systems are comparably safe and effective. AF ablation utilizing the POLARx system is associated with longer procedure and fluoroscopy times as well as lower nadir temperatures.
format Article in Journal/Newspaper
author Denise Guckel
Philipp Lucas
Khuraman Isgandarova
Mustapha El Hamriti
Leonard Bergau
Thomas Fink
Vanessa Sciacca
Guram Imnadze
Martin Braun
Moneeb Khalaph
Georg Nölker
Philipp Sommer
Christian Sohns
author_facet Denise Guckel
Philipp Lucas
Khuraman Isgandarova
Mustapha El Hamriti
Leonard Bergau
Thomas Fink
Vanessa Sciacca
Guram Imnadze
Martin Braun
Moneeb Khalaph
Georg Nölker
Philipp Sommer
Christian Sohns
author_sort Denise Guckel
title News from the Cold Chamber: Clinical Experiences of POLARx versus Arctic Front Advance for Single-Shot Pulmonary Vein Isolation
title_short News from the Cold Chamber: Clinical Experiences of POLARx versus Arctic Front Advance for Single-Shot Pulmonary Vein Isolation
title_full News from the Cold Chamber: Clinical Experiences of POLARx versus Arctic Front Advance for Single-Shot Pulmonary Vein Isolation
title_fullStr News from the Cold Chamber: Clinical Experiences of POLARx versus Arctic Front Advance for Single-Shot Pulmonary Vein Isolation
title_full_unstemmed News from the Cold Chamber: Clinical Experiences of POLARx versus Arctic Front Advance for Single-Shot Pulmonary Vein Isolation
title_sort news from the cold chamber: clinical experiences of polarx versus arctic front advance for single-shot pulmonary vein isolation
publisher MDPI AG
publishDate 2022
url https://doi.org/10.3390/jcdd9010016
https://doaj.org/article/cc4163b335c3488e8c3e1922f6464051
geographic Arctic
geographic_facet Arctic
genre Arctic
genre_facet Arctic
op_source Journal of Cardiovascular Development and Disease, Vol 9, Iss 16, p 16 (2022)
op_relation https://www.mdpi.com/2308-3425/9/1/16
https://doaj.org/toc/2308-3425
doi:10.3390/jcdd9010016
2308-3425
https://doaj.org/article/cc4163b335c3488e8c3e1922f6464051
op_doi https://doi.org/10.3390/jcdd9010016
container_title Journal of Cardiovascular Development and Disease
container_volume 9
container_issue 1
container_start_page 16
_version_ 1766331406726725632